(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release →
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone